An Australian first

Pembrolizumab (Keytruda) is the first medicine to have additional indications registered on the ARTG via the TGA’s provisional approval pathway “Pembrolizumab's indications now include the treatment of patients with metastatic colorectal carcinoma (bowel cancer) and other solid tumours with certain types of mutations (deficient mismatch repair),” the TGA says. It advised that the medicine’s Product